Citius Oncology, Inc. (CTOR) vs LENSAR Inc (LNSR)
A side-by-side comparison of Citius Oncology, Inc. and LENSAR Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTOR
Citius Oncology, Inc.
$0.85HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
LNSR
LENSAR Inc
$6.71HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
Total return — CTOR vs LNSR
growth of $100 · dividends reinvested · last 2yCTOR -92.4% (-72.4%/yr)LNSR +26.3% (+12.4%/yr)LNSR compounded faster over this window
Log scale — wide-divergence pair
CTOR LNSR
CTOR vs LNSR: by the numbers
- •LNSR is the larger company ($82M vs $79M market cap).
- •LNSR is profitable (57.57% net margin) while CTOR runs a net loss (-648.32%).
Metrics side by side
Valuation
| Metric | CTOR | LNSR |
|---|---|---|
| Forward P/E | 8.50 | N/A |
| P/S ratio | 11.12 | 1.37 |
| P/B ratio | 1.96 | 5.53 |
Profitability
| Metric | CTOR | LNSR |
|---|---|---|
| Gross margin | 0.00% | 47.96% |
| Operating margin | 0.00% | -42.06% |
| Net margin | -648.32% | 57.57% |
| ROE | -114.06% | 232.78% |
| ROIC | -88.72% | -16.28% |
Growth (annualized)
| Metric | CTOR | LNSR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 14.67% |
| Total return CAGR (5Y) | N/A | -3.18% |
Frequently asked
- Is CTOR or LNSR more profitable?
- LNSR runs the higher net margin — CTOR at -648.32% versus LNSR at 57.57%.
Go deeper
Dig into the metrics
Citius Oncology ROELENSAR ROECitius Oncology operating marginLENSAR operating marginCitius Oncology revenue growthLENSAR revenue growthCitius Oncology free cash flowLENSAR free cash flow
Citius Oncology & LENSAR appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.